Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis

Figure 1 PRISMA diagram of article selection.

Figure 2 Results of the direct meta-analyses (random effects model) of randomized controlled trials comparing essential phospholipids + antidiabetic therapy with antidiabetic therapy (control). A: Change in alanine aminotransferase levels; B: Change in triglyceride levels; C: Change in total cholesterol levels; D: Relative risk of recovery; E: Relative risk of change in disease; F: Relative risk of final disease severity. EPL: Essential phospholipids; MD: Mean difference; CI: Confidence interval; RE: Random effects; RR: Relative risk; ALT: Alanine aminotransferase.

Figure 3 Results of the indirect meta-analyses (random effects model) comparing essential phospholipids with Chinese herbal medicines in combination with essential phospholipids. A: Change in alanine aminotransferase levels; B: Change in triglyceride levels; C: Relative risk of disease response. EPL: Essential phospholipids; MD: Mean difference; CI: Confidence interval; RR: Relative risk; ALT: Alanine aminotransferase.

Figure 4 Cohort meta-analysis (random effects model) of outcomes in the non-randomized controlled trials. A: Change in alanine aminotransferase levels; B: Change in aspartate aminotransferase levels; C: Proportion of patients with an improvement in disease. CI: Confidence interval; ALT: Alanine aminotransferase; MN: Mean change from baseline; RE: Random effects.

Figure 5 Cohort meta-analysis (random effects model) of outcomes in the randomized controlled trials. A: Change in alanine aminotransferase levels; B: Change in aspartate aminotransferase levels; C: Proportion of patients with disease improvement. CI: Confidence interval; ALT: Alanine aminotransferase; MN: Mean change from baseline; RE: Random effects.